Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3598193 | 0.88 | LMNA (0.57) | ALDH1A1HDAC6L3MBTL1HTTGAA | |
| SCHEMBL3589932 | 0.85 | LMNA (0.47) | ALDH1A1HDAC6L3MBTL1HTTGAA | |
| SCHEMBL3595689 | 0.85 | ALDH1A1 (0.51) | ALDH1A1HDAC6L3MBTL1HTTGAA | |
| SCHEMBL3608186 | 0.84 | KDM4E (0.54) | ALDH1A1HDAC6HTTKDM4ESMN1; SMN2 | |
| SCHEMBL3596889 | 0.83 | HTT (0.66) | ALDH1A1HDAC6L3MBTL1HTTGAA | |
| SCHEMBL3587770 | 0.82 | ALDH1A1 (0.48) | ALDH1A1L3MBTL1HTTGAAKDM4E | |
| SCHEMBL3610556 | 0.81 | KDM4E (0.62) | ALDH1A1L3MBTL1HTTKDM4E | |
| SCHEMBL3599795 | 0.79 | HDAC6 (0.47) | ALDH1A1HDAC6L3MBTL1KDM4ESMN1; SMN2 | |
| SCHEMBL3600244 | 0.77 | GAA (0.58) | ALDH1A1HTTGAAKDM4ESMN1; SMN2 | |
| SCHEMBL3596283 | 0.74 | HDAC6 (0.44) | ALDH1A1HDAC6HTTKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807704-B2 | Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 | CHEMOCENTRYX, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-20070275965-A1 | CXCR4 modulators | CHEMOCENTRYX, INC. (US) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275965-A1 | CXCR4 modulators | CXCL12, CXCR4, CXCR1 | ALDH1A1 662/4885HDAC6 1799/4885L3MBTL1 2170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.